Compare Citius Pharmaceuticals Inc (CTXR) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Firy Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Firy Inc. trades at $8.6 (market cap $125.48M). The key difference: Firy Inc. is far larger — about 8.6× Citius Pharmaceuticals Inc's market cap, and Firy Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FIRY | |
|---|---|---|
Market Cap | $14.64M | $125.48M |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $12.45 |
52-Week Low | $0.53 | $2.28 |
Enterprise Value | $10.86M | $69.16M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
FIRY trades at $8.44, down 1.17% on the day, with a bullish technical signal from moving averages despite recent price weakness. The company reported Q1 2026 revenue growth but continues to post significant losses, with a net income margin of -57.48%. Recent developments include a corporate rebrand from Skillz Inc. and a major legal victory, though cash flow remains negative.
The outlook remains challenging due to persistent unprofitability and negative cash flows, offset by potential from the rebrand and legal win. Risks include high burn rate and competitive pressures. Analyst sentiment is mixed with a hold-dominated consensus, suggesting cautious optimism pending sustained operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
